ARMI | BioFabUSA will be attending ARM’s Cell & Gene Therapy Investor Day.
Now in its 7th year, this one-day meeting provides institutional, strategic and venture investors with unique insight into financing opportunities for cell and gene therapy-based treatment and tools. With significant technological advances and a number of recently approved products, the sector is poised for ever-increasing investor and analyst interest. The event includes clinical and commercial experts on-hand to address specific questions regarding the outlook for these products, and how this sector is impacting key therapeutic areas including oncology, ophthalmology, rare disease, diabetes, cardiovascular disease, wound healing and tissue repair and neurodegenerative diseases. The program includes talks by key opinion leaders in the industry, analysts closely following the sector as well as presentations by more than 30 leading companies from across the globe.